- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Heartbeam Inc. Warrant (BEATW)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: BEATW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -44.64% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 |
52 Weeks Range 0.29 - 0.95 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.31% | Return on Equity (TTM) -164.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5185854 |
Shares Outstanding - | Shares Floating 5185854 | ||
Percent Insiders - | Percent Institutions - |
About Heartbeam Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-11 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 15 | Website |
Full time employees 15 | Website | ||
HeartBeam, Inc., a medical technology company, primarily focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company develops three-dimensional (3D)-vector electrocardiogram (ECG) platform for heart attack detection. It is developing HeartBeam AIMI software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack; and HeartBeam AIMIGo, a credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

